WO1998004267A1 - Progestin/estrogen oral contraceptive - Google Patents

Progestin/estrogen oral contraceptive Download PDF

Info

Publication number
WO1998004267A1
WO1998004267A1 PCT/US1997/012789 US9712789W WO9804267A1 WO 1998004267 A1 WO1998004267 A1 WO 1998004267A1 US 9712789 W US9712789 W US 9712789W WO 9804267 A1 WO9804267 A1 WO 9804267A1
Authority
WO
WIPO (PCT)
Prior art keywords
estrogen
days
progestin
dosage
daily dosage
Prior art date
Application number
PCT/US1997/012789
Other languages
French (fr)
Inventor
Michael Jay Gast
Original Assignee
American Home Products Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corporation filed Critical American Home Products Corporation
Priority to AU38886/97A priority Critical patent/AU3888697A/en
Publication of WO1998004267A1 publication Critical patent/WO1998004267A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Definitions

  • oral contraceptives consist of a combination of a progestin and estrogen that are administered concurrently for 21 days followed either by a 7 day pill free interval or by the administration of a placebo for 7 days in each 28 day cycle.
  • the most important aspects of a successful oral contraceptive product are effective contraception, good cycle control (absence of spotting and breakthrough bleeding and occurrence of withdrawal bleeding), and minimal side effects.
  • Combination oral contraceptives have traditionally acted by suppression of gonadotropins.
  • the progestin component is primarily responsible for contraceptive efficacy through inhibition of ovulation, and other peripheral effects which include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).
  • the estrogenic component intensifies the anovulatory effect of the progestin, and is also important for maintaining cycle control.
  • Ethinyl estradiol is the estrogen most frequently used in combination OCs.
  • the dosage of EE in marketed OC formulations has been steadily reduced from that found in earlier OCs.
  • Thromboembolic mortality decreased when the amount of synthetic estrogen in OC formulations was reduced from 100 ⁇ g to 50 ⁇ g.
  • a significant reduction in fatal myocardial infarctions was reported for women using OCs with 30 ⁇ g of EE rather than 50 ⁇ g of EE. [Meade TW, Br Med J 280:1157 (1980)].
  • progestin/estrogen combination is administered either as a fixed dosage combination (monophasic) or as biphasic or triphasic regimens in which the dosage of the combination is varied either once or twice throughout the menstrual cycle.
  • the progestin/estrogen combination is typically administered for 21 days followed by either a 7-day pill free period or the administration of a non-contraceptive placebo (or iron supplement) for 7 days.
  • 3-ketodesogestrel (3-KDSG), desogestrel (DSG), levonorgestrel (LNg), gestodene (GTD), norgestrel (NG), and norethindrone (NE) are typically used as the progestin while ethinyl estradiol (EE); 17 ⁇ -estradiol, and mestranol are typically the estrogenic components.
  • Other progestins less frequently used include drospirenone (DRSP) and dienogest (DGST).
  • An oral contraceptive product containing a combination of 3 mg DGST and 30 ⁇ g EE for 21 -day administration per cycle is marketed in Germany.
  • Lachnit (PCT Publication WO 95/26730) discloses bridged regimens consisting of the administration of a combination of a progestin/estrogen combination (50 - 125 ⁇ g LNg and 10 - 40 ⁇ g EE) for the first 23-24 days of the menstrual cycle followed by the administration of an estrogen (2 - 40 ⁇ g EE) for 4-10 days for a total administration of at least 28 days per cycle.
  • the use of 100 - 300 ⁇ g drospirenone and 10 - 40 ⁇ g EE as the 23-24 day progestin/estrogen combination is disclosed.
  • Lachnit also discloses a triphasic plus bridging regimen (4-9 days, 4-9 days, 9-13 days, and 28 days for the three phases and estrogen phase, respectively) in which a combination of 50 ⁇ g LNg and 20 ⁇ g EE are administered in the first phase, a combination of 75 ⁇ g LNg and 25 ⁇ g EE are administered in the second phase, a combination of 100 ⁇ g LNg and 20 ⁇ g EE are administered in the third phase, and 10 ⁇ g EE is administered in the estrogen phase.
  • Other progestins disclosed include GTD, DSG, 3-KDSG, DRSP, cyproterone acetate, norgestimate, and norethisterone.
  • Erlich discloses sequential contraceptive regimens consisting of the administration of an estrogen which effects a disturbance of follicle stimulation, followed by the administration of a combination of a progestin/estrogen in a dose at least adequate to inhibit ovulation.
  • the regimen is administered for a total of 28 days per cycle. It is preferred that the estrogen is administered for 5-14 days per cycle and the progestin/estrogen combination is administered for 23- 14 days per cycle, so that the total administration is for 28 days per cycle.
  • Specific regimens include (a) 4 mg estradiol for 7 days followed by 21 days of the combination of 1 mg norethisterone acetate and 4 mg estradiol; (b) 2 mg estradiol valerate for 7 days followed by 21 days of the combination of 2 mg chlormadinone acetate and 4 mg estradiol valerate; and (c) 20 ⁇ g EE followed by 18 days of the combination of 150 ⁇ g LNg and 20 ⁇ g EE.
  • Regimen (c) in Erlich provides a total steroidal load of 2.7 mg of LNg and 560 ⁇ g EE per 28 day cycle.
  • Moore discloses bridged triphasic regimens consisting of the administration of a combination of 10 - 50 ⁇ g LNg and 5 - 20 ⁇ g EE from days 1-7 of the menstrual cycle; of 50 - 75 ⁇ g LNg and 5 - 20 ⁇ g EE from days 8-14 of the menstrual cycle; of 75 - 125 ⁇ g LNg and 5 - 20 ⁇ g EE from days 15-21 of the menstrual cycle; and 5 - 20 ⁇ g EE from days 22-28 of the menstrual cycle.
  • Oettel (EP 696,454 A2) discloses a three phase contraceptive regimen in which the first phase consists of the administration for 3-4 days of a composition containing at least one biogenic estrogen; the second phase consists of the administration for 20-22 days of at least one biogenic estrogen and at least one progestin (progesterone, DGST, desogestrel, 3-KDSG, GTD, LNg, norgestimate, notethisterone, norethisterone acetate, dehydrogestrone, chlormadinone acetate, cyproterone acetate, medroxyprogesterone acetate, or egestrol acetate); and the third phase consists of the administration for 3-4 days of a composition containing at least biogenic one estrogen.
  • progestin progesterone, DGST, desogestrel, 3-KDSG, GTD, LNg, norgestimate, notethisterone, norethisterone acetate, dehydroges
  • WO 95/17194 discloses contraceptive regimens which consist of the administration of a combination of a progestin (50 - 75 ⁇ g GTD, 75 - 125 ⁇ g LNg, 60 - 150 ⁇ g DSG, 60 - 150 ⁇ g 3-KDSG, 100 - 300 ⁇ g DRSP, 100 - 200 ⁇ g cyproterone acetate, 200 - 300 ⁇ g norgestimate, or >350 - 750 ⁇ g norethisterone) and an estrogen (15 - 20 ⁇ g EE or 2 - 6 mg 17 ⁇ -estradiol) for 23-24 days per cycle.
  • a progestin 50 - 75 ⁇ g GTD, 75 - 125 ⁇ g LNg, 60 - 150 ⁇ g DSG, 60 - 150 ⁇ g 3-KDSG, 100 - 300 ⁇ g DRSP, 100 - 200 ⁇ g cyproterone acetate, 200 - 300 ⁇ g n
  • Oettel (EP 628,312 Al) discloses combination contraceptive combinations containing the combination of three components: a biogenic estrogen (estradiol, estrone, or estriol), a synthetic estrogen (EE or mestranol), and a progestin (LNg, desogestrel, progesterone, norethisterone acetate, DGST, chlormadinone acetate, gestodene, or cyproterone acetate).
  • the combination is administered for 21 days followed by the administration of placebo (or pill free) or an estrogen on days 22-28 of the cycle.
  • Upton Upton (EP Patent Specification 253,607 Bl) teaches the use of low dose progestin/estrogen combinations for combined hormone replacement therapy and contraception in climacteric women.
  • Climacteric women are defined in Upton as pre- menopausal women around 40 years of age whose hormone levels are waning. The climacteric woman still ovulates (albeit may have irregular ovulation), but she still experiences many of the symptoms of the hypoestrogenic menopausal woman, such as insomnia, hot flushes, and irritability.
  • Upton teaches the administration of a 23-26 day onophasic regimen of progestin/estrogen followed by a pill free or placebo interval of 2-5 days; with 24 days of progestin/estrogen administration followed by a 4-day pill free or placebo administration being preferred.
  • Upton teaches the use of a progestin selected from 25 - 100 ⁇ g LNg, 10 - 70 ⁇ g GTD, 25 - 100 ⁇ g DSG, 25 - 100 ⁇ g 3- KDSG, and 85 - 350 ⁇ g NE used in combination with an estrogen selected from 500 - 2000 ⁇ g 17 ⁇ -est ⁇ adiol, 8 - 30 ⁇ g EE, and 15 - 60 ⁇ g mestranol.
  • Upton Based on relative potencies, Upton teaches that a dose of 75 ⁇ g LNg is equivalent to 35 ⁇ g of GTD, 75 ⁇ g of 3-KDSG or DSG, and 250 ⁇ g NE and that a dose of 1000 ⁇ g of 17 ⁇ -estradiol is equivalent to a dose of 15 ⁇ g EE and 30 ⁇ g mestranol. Upton also teaches that NG may be substituted for LNg, but at twice the dose.
  • Sartoretto (Clinica e Terapeutica 3: 399 (1974)) discloses a monophasic contraceptive regimen consisting of the administration of a combination 100 ⁇ g LNg and 20 ⁇ g EE for 21 days.
  • Lachnit-Fixson (U.S. Patent 3,969,502) discloses biphasic progestin/estrogen combination regimens in which a combination of 50-125 ⁇ g LNg and 25-35 ⁇ g EE are administered for 10-12 days in the first phase and 100-350 ⁇ g LNg and 30-50 ⁇ g EE are administered for 10-12 days in the second phase.
  • Placebo is administered for 5-7 days following the administration of the contraceptive steroid regimen.
  • Lachnit-Fixson U.S. Patent 3,957,982 discloses triphasic 21 -day progestin/estrogen regimens in which a combination of 40-90 ⁇ g LNg and 20-50 ⁇ g EE is administered for 4-6 days in the first phase, 50-125 ⁇ g LNg and 30-50 ⁇ g EE is administered for 4-6 days in the second phase, and 100-250 ⁇ g LNg and 25-50 ⁇ g EE is administered for 9-11 days in the third phase. It is preferred that the first, second, and third phases are 6, 5, and 10 days, respectively. Bennick (U.S.
  • Patent 5,418,2278 discloses triphasic regimens which consist of the administration of a combination progestin/estrogen in a 6-8 day phase, a second 6-8 day phase, and a third 6-8 day phase, with it being preferred that the three contraceptive steroid phases be 7 days each.
  • the first contraceptive steroid phase consists of a progestin at a daily dosage equivalent to 75 - 150 ⁇ g DSG and an estrogen at a daily dosage equivalent to 20 - 25 ⁇ g EE;
  • the second contraceptive steroid phase consists of a progestin at a daily dosage equivalent to 75 - 125 ⁇ g DSG and an estrogen at a daily dosage equivalent to 20 ⁇ g EE;
  • the third contraceptive steroid phase consists of a progestin at a daily dosage equivalent to 75 - 100 ⁇ g DSG and an estrogen at a daily dosage equivalent to 20 ⁇ g EE.
  • Placebo is administered for 7 days following the 21 -day contraceptive steroid period.
  • Bennick discloses that the progestin may be 3-KDSG, DSG, LNg, or GTD.
  • the Bergink discloses a 24 day triphasic combination regimen in which the first 7-9 day phase consists of the administration of a progestin at a daily dosage equivalent to 100 ⁇ g DSG and an estrogen at a daily dosage equivalent to 25 ⁇ g EE, the second 7-9 day phase consists of the administration of a progestin at a daily dosage equivalent to 125 ⁇ g DSG and an estrogen at a daily dosage equivalent to 20 ⁇ g EE, and the third 7-9 day phase consists of the administration of a progestin at a daily dosage equivalent to 50 ⁇ g DSG and an estrogen at a daily dosage equivalent to 20 ⁇ g EE. It is preferred that the three phases be 8 days each. Following the 24 day contraceptive steroid administration, a placebo may be administered for 4 days, the 4 day interval may be pill free, or a progestin at a dosage equivalent to 25-35 ⁇ g DSG may be administered.
  • Boissonneault U.S. Patent 4,962,098 discloses triphasic progestin/estrogen combinations in which the amount of the estrogenic component is increased stepwise over the three phases. Contraceptive steroid combinations are taken for 4-7 days during the first phase (5 days being preferred); for 5-8 days during the second phase (7 days preferred); and for 7-12 days during the third phase (9 days being preferred). Following the administration of 21 -days of the contraceptive steroid combination, placebo is taken for 7 days. For all three phases, 0.5-1.5 mg of norethindrone acetate is used in the progestin, with 1 mg being preferred. 10-30 ⁇ g EE is used in the first phase, 20-40 ⁇ g in the second, and 30-50 ⁇ g in the third phase.
  • Pasquale U.S. Patent 4,921,843 discloses combination progestin/estrogen contraceptive regimens which contain 0.5 to 1 mg of progestin and an estrogen having a dose equivalent to 10-40 ⁇ g of EE.
  • NE, LNg, D-17 ⁇ -acetoxy-13 ⁇ -ethyI-17 ⁇ -ethinyl- gon-4-en-3-one oxime, and 19-nor-17-hydroxy progesterone ester are disclosed as progestins, with NE being preferred.
  • Specifically disclosed regimens include a uniphasic regimen (2 days of placebo, 5 days of 20 ⁇ g EE, and 21 days of a combination of 500 ⁇ g NE and 35 ⁇ g EE); a uniphasic regimen (2 days of placebo, 5 days of 40 ⁇ g EE, and 21 days of a combination of 500 ⁇ g NE and 35 ⁇ g EE); and a triphasic regimen (2 days of placebo; 5 days of 20-40 ⁇ g EE; 7 days of a combination of 500 ⁇ g NE and 35 ⁇ g EE; 7 days of a combination of 750 ⁇ g NE and 35 ⁇ g EE; and 7 days of a combination of 1 mg NE and 35 ⁇ g EE).
  • Pasquale U.S. Patent 4,628,051 discloses triphasic progestin/estrogen combination regimens in which contraceptive steroid is administered for 21 days. Contraceptive steroid combinations are taken for 5-8 days during the first phase (7 days being preferred); for 7-11 days during the second phase (7 days preferred); and for 3-7 days during the third phase (7 days being preferred). In all three phases, an estrogen at a daily dosage equivalent to 20-50 ⁇ g EE is administered in combination with a progestin having a daily dosage equivalent to 65-750 ⁇ g NE in the first phase, 0.25-1.0 mg NE in the second phase, and 0.35-2.0 mg NE in the third phase.
  • a specific triphasic regimen discloses the administration of 35 ⁇ g EE in each of the three 7-day phases in combination with 0.5 mg, 0.75 mg, and 1.0 mg in the first, second, and third phases, respectively.
  • a second specific triphasic regimen discloses the administration of 35 ⁇ g EE in each of the three 7-day phases in combination with 50 ⁇ g, 75 ⁇ g, and 100 ⁇ g in the first, second, and third phases, respectively.
  • a third specific triphasic regimen discloses the administration of 35 ⁇ g EE in each of the three 7-day phases in combination with 25 ⁇ g, 35 ⁇ g, and 50 ⁇ g in the first, second, and third phases, respectively.
  • Lachnit-Fixson U.S. Patent 4,621,079 discloses triphasic 21-day progestin/estrogen combination regimens in which a combination of 40-70 ⁇ g GTD and 20-35 ⁇ g EE is administered for 4-6 days in the first phase; 50- 100 ⁇ g GTD and 30-50 ⁇ g EE is administered for 4-6 days in the second phase; and 80-120 ⁇ g GTD and 20-50 ⁇ g EE is administered for 9-11 days in the third phase. Placebo is administered for 7 days following the 21 -day contraceptive steroid regimen.
  • Pasquale U.S. Patent 4,530,839 discloses triphasic 21-day progestin/estrogen combination regimens in which a dose of 20-50 ⁇ g EE is administered in all three phases in combination with a contraceptively effective daily dose of progestin in the first phase, 1.5-2 times that dose of progestin in the second phase, and 2-2.5 times the first phase dose of progestin in the third phase.
  • Each of the three phases is 7 days long.
  • a specific regimen discloses 20-50 ⁇ g EE in combination with 500 ⁇ g LNg, 750 ⁇ g LNg, and 1 mg LNg during each of the three 7-day phases, respectively.
  • Edgren U.S. Patent 4,390,531 discloses triphasic 21 -day progestin/estrogen combination regimens in which a dose of 20-40 ⁇ g EE (or another estrogen in an equivalent dosage) is administered in all three phases in combination with 0.3-0.8 mg NE (or another progestin in an equivalent dosage) for 5-8 days in the first phase, twice the dose of NE for 7-11 days in the second phase, and the dose of NE being the same as in the first phase for 3-7 days in the third phase. It is preferred that each of the three phases is 7 days. Placebo is administered for 6-8 days following administration of the contraceptive steroid combination.
  • a specific regimen discloses a first phase of 7 days of 0.5 mg NE in combination with 35 ⁇ g EE, a second 7 day phase of 1.0 mg NE in combination with 35 ⁇ g EE, and a third 7 day phase of 0.5 mg NE in combination with 35 ⁇ g EE.
  • This invention provides a bridged monophasic combination progestin/estrogen oral contraceptive regimen for females of child-bearing age that provides effective contraception, good cycle control, and minimal side effects while greatly reducing the total contraceptive steroid administered (particularly the estrogenic component) per 28- day cycle.
  • the low dose progestin/estrogen combination is administered for 23-25-days per cycle followed by the administration of an estrogen for the remaining 3-5 days of the cycle.
  • Administration of the contraceptive progestin/estrogen combination is begun on the first day of menses (day 1), and continued for 23-25 consecutive days. Following the 23- 25-day administration period, an estrogen is administered for 3-5 days to assist in maintaining good cycle control. The total administration during each cycle is 28 days.
  • this invention provides a method of contraception which comprises administering to a female of child bearing age a combination of 40-500 ⁇ g trimegestone, 250 ⁇ g - 4 mg dienogest, or 250 ⁇ g - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 ⁇ g ethinyl estradiol for 23-25 days beginning on day 1 of the menstrual cycle. Following the 23-25-day period, an estrogen at a daily dosage equivalent to 5-15 ⁇ g ethinyl estradiol is administered for 3-5 days. The total administration during each cycle is 28 days.
  • Preferred estrogens include, but are not limited to ethinyl estradiol; 17 ⁇ - estradiol; conjugated estrogens, USP; estrone or a salt thereof; and mestranol; with ethinyl estradiol being more preferred.
  • ethinyl estradiol is used as the estrogen during the first 23-25 days of the cycle, it is preferred that the daily dosage of ethinyl estradiol is 10-20 ⁇ g, with 15 ⁇ g being more preferred.
  • the daily dosage of ethinyl estradiol is 5-15 ⁇ g, with 15 ⁇ g being more preferred.
  • the daily dosage of 17 ⁇ -estradiol is 1-3 ⁇ g.
  • Preferred salts of estrone include, but are not limited to the sodium and piperate salt.
  • conjugated estrogens USP are used as the estrogen, it is preferred that the daily dosage is 0.3-5 mg, with a daily dose of 1.25 mg conjugated estrogens, USP being equivalent to a daily dose of 15 ⁇ g ethinyl estradiol.
  • the progestin/estrogen combination be administered for 24 days beginning on day 1 of the menstrual cycle, and following this 24-day period, it is preferred that the estrogen be administered for 4 days.
  • the following daily dosages of a combination of trimegestone and ethinyl estradiol are preferred for contraception when administered for 23-25 consecutive days beginning on the first day of menses, followed by the administration of ethinyl estradiol for 3-5 days.
  • the total administration during each cycle is 28 days. It is preferred that the dose of ethinyl estradiol during the 3-5 day period be the same as the dose of ethinyl estradiol that was administered during the 24 day period, or lower.
  • Regimen B is most preferred. PREFERRED DAILY DOSAGES
  • the combination progestin/estrogen contraceptive be administered in unit dosage form i.e., tablet or pill, with each unit providing the entire daily dosage. It is preferred that the progestin and estrogen are admixed together in the same dosage unit. Such dosage units can be prepared by conventional methodology that is well known to one skilled in the art. In each dosage unit, the contraceptively active progestin and estrogen are combined with excipients, vehicles, pharmaceutically acceptable carriers, and colorants. For example, the following illustrates an acceptable composition of a contraceptive progestin/estrogen combination of this invention.
  • Ethinyl estradiol 15 ⁇ g Microcrystaline Cellulose Lactose, NF, Spray Dried Polacrillin Potassium, NF Magnesium Stearate
  • the estrogen be administered in unit dosage form i.e., tablet or pill, with each unit providing the entire daily dosage.
  • unit dosage form i.e., tablet or pill
  • each unit providing the entire daily dosage.
  • dosage units can be prepared by conventional methodology that is well known to one skilled in the art.
  • the estrogen is combined with excipients, vehicles, pharmaceutically acceptable carriers, and colorants.
  • excipients, vehicles, pharmaceutically acceptable carriers, and colorants for example, the following illustrates an acceptable estrogen composition of this invention.
  • EXAMPLE 2 illustrates an acceptable estrogen composition of this invention.
  • This invention also provides a contraceptive kit adapted for daily oral administration which comprises a total of 28 separate dosage units.
  • this kit 23-25 dosage units each consisting of a combination of 40-500 ⁇ g trimegestone, 250 ⁇ g - 4 mg dienogest, or 250 ⁇ g - 4 mg drospirenone and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 ⁇ g ethinyl estradiol.
  • the remaining 3-5 dosage units contain an estrogen at a daily dosage equivalent in estrogenic activity to 5-15 ⁇ g ethinyl estradiol.
  • the daily dosage arrangements are preferably arranged in a blister pack or in a dial pack type tablet dispenser. Specific referred progestins and estrogens and the specifically preferred dosages of each combination dosage unit are described above.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides a method of contraception which comprises administering to a female of child-bearing age a combination of a progestin at a daily dosage of 40-500 νg trimegestone, 250 νg - 4 mg dienogest, or 250 νg - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 νg ethinyl estradiol for 23-25 days beginning on day 1 of the menstrual cycle; wherein the same dosage of the progestin and estrogen combination is administered in each of the 23-25 days, followed by the administration of an estrogen at a daily dosage equivalent in estrogenic activity to 5-15 νg ethinyl estradiol for 3-5 days; wherein the same dosage of the estrogen is administered in each of the 3-5 days; such that the number of days of administration of the progestin and estrogen combination plus the number of days of administration of estrogen is equal to 28 per menstrual cycle.

Description

PROGESTIN/ESTROGEN ORAL CONTRACEPTIVE
BACKGROUND OF THE INVENTION
The vast majority of oral contraceptives consist of a combination of a progestin and estrogen that are administered concurrently for 21 days followed either by a 7 day pill free interval or by the administration of a placebo for 7 days in each 28 day cycle. The most important aspects of a successful oral contraceptive product are effective contraception, good cycle control (absence of spotting and breakthrough bleeding and occurrence of withdrawal bleeding), and minimal side effects. Combination oral contraceptives have traditionally acted by suppression of gonadotropins. In addition, it appears that the progestin component is primarily responsible for contraceptive efficacy through inhibition of ovulation, and other peripheral effects which include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation). The estrogenic component intensifies the anovulatory effect of the progestin, and is also important for maintaining cycle control.
Since the introduction of oral contraceptives (OCs) over a quarter-century ago, research has been directed toward developing preparations that minimize the potential for side effects while maintaining efficacy and normal menstrual patterns. The first- generation OCs contained more progestin and estrogen than was necessary to prevent conception. Adverse hemostatic and metabolic changes, clinical problems, and side effects were associated with these high-dose preparations. In 1978, the World Health Organization (WHO) recommended that the focus of OC research should be the development of products containing the lowest possible dose levels of estrogen and progestin.
The first reductions in steroid content in a combination pill were focused on estrogen because it, rather than progestin, was thought to be related to the most serious side effects. Reduction in progestin content followed, as evidence mounted that lowering progestin intake might lower the risk of cardiovascular complications such as stroke and ischemic heart disease. [Kay CR, Am J Obstet Gynecol 142:762 (1982)]. However, this evidence was not as clear as that implicating estrogen in thromboembolic disorders. [Inman WHW, Br Med J 2:203 (1970); Stolley PD, Am J Epidemiol 102: 197 (1975)]. The need for a balance between estrogens and progestins to minimize adverse effects on carbohydrate metabolism and on lipid and lipoprotein levels was also recognized. [Bradley DD, N Engl J Med 299:17 (1978); Wynn V, Lancet 1:1045 (1979)]. Researchers then found that the synergistic action between progestin and estrogen in a balanced ratio successfully inhibited ovulation at low levels of both components. Research into low-dose progestins was advanced significantly by the development of norgestrel (Ng) and levonorgestrel (LNg). Levonorgestrel is the biologically active moiety of racemic norgestrel. It is strongly progestational, has no inherent estrogenic activity, is antiestrogenic, and possesses good biologic activity. The contraceptive effects of levonorgestrel are manifested throughout the hypothalamic- pituitary-gonadal-target organ axis.
Ethinyl estradiol (EE) is the estrogen most frequently used in combination OCs. In attempts to fulfill the WHO objective, the dosage of EE in marketed OC formulations has been steadily reduced from that found in earlier OCs. Thromboembolic mortality decreased when the amount of synthetic estrogen in OC formulations was reduced from 100 μg to 50 μg. Subsequently, a significant reduction in fatal myocardial infarctions was reported for women using OCs with 30 μg of EE rather than 50 μg of EE. [Meade TW, Br Med J 280:1157 (1980)].
In keeping with the goal of reducing the total steroidal dosage, while maintaining contraceptive efficacy, good cycle control, and minimizing side effects, numerous regimens have been developed in which the progestin/estrogen combination is administered either as a fixed dosage combination (monophasic) or as biphasic or triphasic regimens in which the dosage of the combination is varied either once or twice throughout the menstrual cycle. In these regimens, the progestin/estrogen combination is typically administered for 21 days followed by either a 7-day pill free period or the administration of a non-contraceptive placebo (or iron supplement) for 7 days. In these regimens, 3-ketodesogestrel (3-KDSG), desogestrel (DSG), levonorgestrel (LNg), gestodene (GTD), norgestrel (NG), and norethindrone (NE) are typically used as the progestin while ethinyl estradiol (EE); 17β-estradiol, and mestranol are typically the estrogenic components. Other progestins less frequently used include drospirenone (DRSP) and dienogest (DGST).
An oral contraceptive product containing a combination of 3 mg DGST and 30 μg EE for 21 -day administration per cycle is marketed in Germany.
Several examples of attempts at reducing the total steroidal dosage are provided below. Lachnit (PCT Publication WO 95/26730) discloses bridged regimens consisting of the administration of a combination of a progestin/estrogen combination (50 - 125 μg LNg and 10 - 40 μg EE) for the first 23-24 days of the menstrual cycle followed by the administration of an estrogen (2 - 40 μg EE) for 4-10 days for a total administration of at least 28 days per cycle. The use of 100 - 300 μg drospirenone and 10 - 40 μg EE as the 23-24 day progestin/estrogen combination is disclosed. Lachnit also discloses a triphasic plus bridging regimen (4-9 days, 4-9 days, 9-13 days, and 28 days for the three phases and estrogen phase, respectively) in which a combination of 50 μg LNg and 20 μg EE are administered in the first phase, a combination of 75 μg LNg and 25 μg EE are administered in the second phase, a combination of 100 μg LNg and 20 μg EE are administered in the third phase, and 10 μg EE is administered in the estrogen phase. Other progestins disclosed include GTD, DSG, 3-KDSG, DRSP, cyproterone acetate, norgestimate, and norethisterone.
Erlich (German Patent DE 4,104,385 Cl and U.S. Patent 5,280,023) discloses sequential contraceptive regimens consisting of the administration of an estrogen which effects a disturbance of follicle stimulation, followed by the administration of a combination of a progestin/estrogen in a dose at least adequate to inhibit ovulation. The regimen is administered for a total of 28 days per cycle. It is preferred that the estrogen is administered for 5-14 days per cycle and the progestin/estrogen combination is administered for 23- 14 days per cycle, so that the total administration is for 28 days per cycle. Specific regimens include (a) 4 mg estradiol for 7 days followed by 21 days of the combination of 1 mg norethisterone acetate and 4 mg estradiol; (b) 2 mg estradiol valerate for 7 days followed by 21 days of the combination of 2 mg chlormadinone acetate and 4 mg estradiol valerate; and (c) 20 μg EE followed by 18 days of the combination of 150 μg LNg and 20 μg EE. Regimen (c) in Erlich provides a total steroidal load of 2.7 mg of LNg and 560 μg EE per 28 day cycle. Moore (DE 4313926 Al) discloses bridged triphasic regimens consisting of the administration of a combination of 10 - 50 μg LNg and 5 - 20 μg EE from days 1-7 of the menstrual cycle; of 50 - 75 μg LNg and 5 - 20 μg EE from days 8-14 of the menstrual cycle; of 75 - 125 μg LNg and 5 - 20 μg EE from days 15-21 of the menstrual cycle; and 5 - 20 μg EE from days 22-28 of the menstrual cycle. Oettel (EP 696,454 A2) discloses a three phase contraceptive regimen in which the first phase consists of the administration for 3-4 days of a composition containing at least one biogenic estrogen; the second phase consists of the administration for 20-22 days of at least one biogenic estrogen and at least one progestin (progesterone, DGST, desogestrel, 3-KDSG, GTD, LNg, norgestimate, notethisterone, norethisterone acetate, dehydrogestrone, chlormadinone acetate, cyproterone acetate, medroxyprogesterone acetate, or egestrol acetate); and the third phase consists of the administration for 3-4 days of a composition containing at least biogenic one estrogen.
Spona (PCT Publication WO 95/17194) discloses contraceptive regimens which consist of the administration of a combination of a progestin (50 - 75 μg GTD, 75 - 125 μg LNg, 60 - 150 μg DSG, 60 - 150 μg 3-KDSG, 100 - 300 μg DRSP, 100 - 200 μg cyproterone acetate, 200 - 300 μg norgestimate, or >350 - 750 μg norethisterone) and an estrogen (15 - 20 μg EE or 2 - 6 mg 17β-estradiol) for 23-24 days per cycle.
Oettel (EP 628,312 Al) discloses combination contraceptive combinations containing the combination of three components: a biogenic estrogen (estradiol, estrone, or estriol), a synthetic estrogen (EE or mestranol), and a progestin (LNg, desogestrel, progesterone, norethisterone acetate, DGST, chlormadinone acetate, gestodene, or cyproterone acetate). In one embodiment, the combination is administered for 21 days followed by the administration of placebo (or pill free) or an estrogen on days 22-28 of the cycle. Upton (EP Patent Specification 253,607 Bl) teaches the use of low dose progestin/estrogen combinations for combined hormone replacement therapy and contraception in climacteric women. Climacteric women are defined in Upton as pre- menopausal women around 40 years of age whose hormone levels are waning. The climacteric woman still ovulates (albeit may have irregular ovulation), but she still experiences many of the symptoms of the hypoestrogenic menopausal woman, such as insomnia, hot flushes, and irritability. Upton teaches the administration of a 23-26 day onophasic regimen of progestin/estrogen followed by a pill free or placebo interval of 2-5 days; with 24 days of progestin/estrogen administration followed by a 4-day pill free or placebo administration being preferred. Upton teaches the use of a progestin selected from 25 - 100 μg LNg, 10 - 70 μg GTD, 25 - 100 μg DSG, 25 - 100 μg 3- KDSG, and 85 - 350 μg NE used in combination with an estrogen selected from 500 - 2000 μg 17β-estτadiol, 8 - 30 μg EE, and 15 - 60 μg mestranol. Based on relative potencies, Upton teaches that a dose of 75 μg LNg is equivalent to 35 μg of GTD, 75 μg of 3-KDSG or DSG, and 250 μg NE and that a dose of 1000 μg of 17β-estradiol is equivalent to a dose of 15 μg EE and 30 μg mestranol. Upton also teaches that NG may be substituted for LNg, but at twice the dose.
Sartoretto (Clinica e Terapeutica 3: 399 (1974)) discloses a monophasic contraceptive regimen consisting of the administration of a combination 100 μg LNg and 20 μg EE for 21 days. Lachnit-Fixson (U.S. Patent 3,969,502) discloses biphasic progestin/estrogen combination regimens in which a combination of 50-125 μg LNg and 25-35 μg EE are administered for 10-12 days in the first phase and 100-350 μg LNg and 30-50 μg EE are administered for 10-12 days in the second phase. Placebo is administered for 5-7 days following the administration of the contraceptive steroid regimen.
Lachnit-Fixson (U.S. Patent 3,957,982) discloses triphasic 21 -day progestin/estrogen regimens in which a combination of 40-90 μg LNg and 20-50 μg EE is administered for 4-6 days in the first phase, 50-125 μg LNg and 30-50 μg EE is administered for 4-6 days in the second phase, and 100-250 μg LNg and 25-50 μg EE is administered for 9-11 days in the third phase. It is preferred that the first, second, and third phases are 6, 5, and 10 days, respectively. Bennick (U.S. Patent 5,418,228) discloses triphasic regimens which consist of the administration of a combination progestin/estrogen in a 6-8 day phase, a second 6-8 day phase, and a third 6-8 day phase, with it being preferred that the three contraceptive steroid phases be 7 days each. Bennick discloses that the first contraceptive steroid phase consists of a progestin at a daily dosage equivalent to 75 - 150 μg DSG and an estrogen at a daily dosage equivalent to 20 - 25 μg EE; the second contraceptive steroid phase consists of a progestin at a daily dosage equivalent to 75 - 125 μg DSG and an estrogen at a daily dosage equivalent to 20 μg EE; and the third contraceptive steroid phase consists of a progestin at a daily dosage equivalent to 75 - 100 μg DSG and an estrogen at a daily dosage equivalent to 20 μg EE. Placebo is administered for 7 days following the 21 -day contraceptive steroid period. Bennick discloses that the progestin may be 3-KDSG, DSG, LNg, or GTD.
Bergink (U.S. Patent 5,262,408) discloses a 24 day triphasic combination regimen in which the first 7-9 day phase consists of the administration of a progestin at a daily dosage equivalent to 100 μg DSG and an estrogen at a daily dosage equivalent to 25 μg EE, the second 7-9 day phase consists of the administration of a progestin at a daily dosage equivalent to 125 μg DSG and an estrogen at a daily dosage equivalent to 20 μg EE, and the third 7-9 day phase consists of the administration of a progestin at a daily dosage equivalent to 50 μg DSG and an estrogen at a daily dosage equivalent to 20 μg EE. It is preferred that the three phases be 8 days each. Following the 24 day contraceptive steroid administration, a placebo may be administered for 4 days, the 4 day interval may be pill free, or a progestin at a dosage equivalent to 25-35 μg DSG may be administered.
Boissonneault (U.S. Patent 4,962,098) discloses triphasic progestin/estrogen combinations in which the amount of the estrogenic component is increased stepwise over the three phases. Contraceptive steroid combinations are taken for 4-7 days during the first phase (5 days being preferred); for 5-8 days during the second phase (7 days preferred); and for 7-12 days during the third phase (9 days being preferred). Following the administration of 21 -days of the contraceptive steroid combination, placebo is taken for 7 days. For all three phases, 0.5-1.5 mg of norethindrone acetate is used in the progestin, with 1 mg being preferred. 10-30 μg EE is used in the first phase, 20-40 μg in the second, and 30-50 μg in the third phase.
Pasquale (U.S. Patent 4,921,843) discloses combination progestin/estrogen contraceptive regimens which contain 0.5 to 1 mg of progestin and an estrogen having a dose equivalent to 10-40 μg of EE. NE, LNg, D-17β-acetoxy-13β-ethyI-17α-ethinyl- gon-4-en-3-one oxime, and 19-nor-17-hydroxy progesterone ester are disclosed as progestins, with NE being preferred. Specifically disclosed regimens include a uniphasic regimen (2 days of placebo, 5 days of 20 μg EE, and 21 days of a combination of 500 μg NE and 35 μg EE); a uniphasic regimen (2 days of placebo, 5 days of 40 μg EE, and 21 days of a combination of 500 μg NE and 35 μg EE); and a triphasic regimen (2 days of placebo; 5 days of 20-40 μg EE; 7 days of a combination of 500 μg NE and 35 μg EE; 7 days of a combination of 750 μg NE and 35 μg EE; and 7 days of a combination of 1 mg NE and 35 μg EE).
Pasquale (U.S. Patent 4,628,051) discloses triphasic progestin/estrogen combination regimens in which contraceptive steroid is administered for 21 days. Contraceptive steroid combinations are taken for 5-8 days during the first phase (7 days being preferred); for 7-11 days during the second phase (7 days preferred); and for 3-7 days during the third phase (7 days being preferred). In all three phases, an estrogen at a daily dosage equivalent to 20-50 μg EE is administered in combination with a progestin having a daily dosage equivalent to 65-750 μg NE in the first phase, 0.25-1.0 mg NE in the second phase, and 0.35-2.0 mg NE in the third phase. A specific triphasic regimen discloses the administration of 35 μg EE in each of the three 7-day phases in combination with 0.5 mg, 0.75 mg, and 1.0 mg in the first, second, and third phases, respectively. A second specific triphasic regimen discloses the administration of 35 μg EE in each of the three 7-day phases in combination with 50 μg, 75 μg, and 100 μg in the first, second, and third phases, respectively. A third specific triphasic regimen discloses the administration of 35 μg EE in each of the three 7-day phases in combination with 25 μg, 35 μg, and 50 μg in the first, second, and third phases, respectively.
Lachnit-Fixson (U.S. Patent 4,621,079) discloses triphasic 21-day progestin/estrogen combination regimens in which a combination of 40-70 μg GTD and 20-35 μg EE is administered for 4-6 days in the first phase; 50- 100 μg GTD and 30-50 μg EE is administered for 4-6 days in the second phase; and 80-120 μg GTD and 20-50 μg EE is administered for 9-11 days in the third phase. Placebo is administered for 7 days following the 21 -day contraceptive steroid regimen.
Pasquale (U.S. Patent 4,530,839) discloses triphasic 21-day progestin/estrogen combination regimens in which a dose of 20-50 μg EE is administered in all three phases in combination with a contraceptively effective daily dose of progestin in the first phase, 1.5-2 times that dose of progestin in the second phase, and 2-2.5 times the first phase dose of progestin in the third phase. Each of the three phases is 7 days long. A specific regimen discloses 20-50 μg EE in combination with 500 μg LNg, 750 μg LNg, and 1 mg LNg during each of the three 7-day phases, respectively.
Edgren (U.S. Patent 4,390,531) discloses triphasic 21 -day progestin/estrogen combination regimens in which a dose of 20-40 μg EE (or another estrogen in an equivalent dosage) is administered in all three phases in combination with 0.3-0.8 mg NE (or another progestin in an equivalent dosage) for 5-8 days in the first phase, twice the dose of NE for 7-11 days in the second phase, and the dose of NE being the same as in the first phase for 3-7 days in the third phase. It is preferred that each of the three phases is 7 days. Placebo is administered for 6-8 days following administration of the contraceptive steroid combination. A specific regimen discloses a first phase of 7 days of 0.5 mg NE in combination with 35 μg EE, a second 7 day phase of 1.0 mg NE in combination with 35 μg EE, and a third 7 day phase of 0.5 mg NE in combination with 35 μg EE.
DESCRIPTION OF THE INVENTION
This invention provides a bridged monophasic combination progestin/estrogen oral contraceptive regimen for females of child-bearing age that provides effective contraception, good cycle control, and minimal side effects while greatly reducing the total contraceptive steroid administered (particularly the estrogenic component) per 28- day cycle. To achieve the substantial reduction in the total contraceptive steroid administered per cycle while maintaining good cycle control, the low dose progestin/estrogen combination is administered for 23-25-days per cycle followed by the administration of an estrogen for the remaining 3-5 days of the cycle. Administration of the contraceptive progestin/estrogen combination is begun on the first day of menses (day 1), and continued for 23-25 consecutive days. Following the 23- 25-day administration period, an estrogen is administered for 3-5 days to assist in maintaining good cycle control. The total administration during each cycle is 28 days.
More particularly, this invention provides a method of contraception which comprises administering to a female of child bearing age a combination of 40-500 μg trimegestone, 250 μg - 4 mg dienogest, or 250 μg - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 μg ethinyl estradiol for 23-25 days beginning on day 1 of the menstrual cycle. Following the 23-25-day period, an estrogen at a daily dosage equivalent to 5-15 μg ethinyl estradiol is administered for 3-5 days. The total administration during each cycle is 28 days. Preferred estrogens include, but are not limited to ethinyl estradiol; 17β- estradiol; conjugated estrogens, USP; estrone or a salt thereof; and mestranol; with ethinyl estradiol being more preferred. When ethinyl estradiol is used as the estrogen during the first 23-25 days of the cycle, it is preferred that the daily dosage of ethinyl estradiol is 10-20 μg, with 15 μg being more preferred. When ethinyl estradiol is used as the estrogen during the last 3-5 days of the cycle, it is preferred that the daily dosage of ethinyl estradiol is 5-15 μg, with 15 μg being more preferred. When 17β-estradiol is used as the estrogen during the last 3-5 days of the cycle, it is preferred that the daily dosage of 17β-estradiol is 1-3 μg. Preferred salts of estrone include, but are not limited to the sodium and piperate salt. When conjugated estrogens, USP are used as the estrogen, it is preferred that the daily dosage is 0.3-5 mg, with a daily dose of 1.25 mg conjugated estrogens, USP being equivalent to a daily dose of 15 μg ethinyl estradiol.
It is preferred that the progestin/estrogen combination be administered for 24 days beginning on day 1 of the menstrual cycle, and following this 24-day period, it is preferred that the estrogen be administered for 4 days. The following daily dosages of a combination of trimegestone and ethinyl estradiol are preferred for contraception when administered for 23-25 consecutive days beginning on the first day of menses, followed by the administration of ethinyl estradiol for 3-5 days. The total administration during each cycle is 28 days. It is preferred that the dose of ethinyl estradiol during the 3-5 day period be the same as the dose of ethinyl estradiol that was administered during the 24 day period, or lower. Regimen B is most preferred. PREFERRED DAILY DOSAGES
First 23-25 Cvcle Davs Last 3-5 Cvcle Davs
Regimen Trimegestone Ethinvl Estradiol Ethinvl Estradiol
A 250 μg 15 μg 5-15 μg
B 125 μg 15 μg 5-15 μg
C 75 μg 15 μg 5-15 μg
D 50 μg 15 μg 5-15 μg
E 40 μg 15 μg 5-15 μg
The following daily dosages of a combination of dienogest and ethinyl estradiol are preferred for contraception when administered for 23-25 consecutive days beginning on the first day of menses. Regimen B is most preferred.
PREFERRED DAILY DOSAGES
First 23-25 Cvcle Davs Last 3-5 Cvcle Davs
Regimen Dienogest Ethinvl Estradiol Ethinvl Estradiol
A 2 mg 15 μg 5- 15 μg
B l mg 15 μg 5-15 μg
C 800 μg 15 μg 5-15 μg
D 750 μg 15 μg 5-15 μg
E 500 μg 15 μg 5-15 μg
The following daily dosages of a combination of drospirenone and ethinyl estradiol are preferred for contraception when administered for 23-25 consecutive days beginning on the first day of menses. Regimen C is most preferred.
PREFERRED DAILY DOSAGES First 23-25 Cvcle Davs Last 3-5 Cvcle Davs
Regimen Drospirenone Ethinvl Estradiol Ethinvl Estradiol
A 3 mg 15 μg 5-15 μg
B 2 mg 15 μg 5-15 μg
C l mg 15 μg 5-15 μg
D 500 μg 15 μg 5-15 μg For administration during the first 23-25 days of the menstrual cycle, it is preferred that the combination progestin/estrogen contraceptive be administered in unit dosage form i.e., tablet or pill, with each unit providing the entire daily dosage. It is preferred that the progestin and estrogen are admixed together in the same dosage unit. Such dosage units can be prepared by conventional methodology that is well known to one skilled in the art. In each dosage unit, the contraceptively active progestin and estrogen are combined with excipients, vehicles, pharmaceutically acceptable carriers, and colorants. For example, the following illustrates an acceptable composition of a contraceptive progestin/estrogen combination of this invention.
EXAMPLE 1
Trimegestone, 125 μg
Ethinyl estradiol, 15 μg Microcrystaline Cellulose Lactose, NF, Spray Dried Polacrillin Potassium, NF Magnesium Stearate
Opadry Pink
Polyethylene Glycol, 1500, Flakes Water, Purified, USP Wax E (Pharma)
For administration during the last 3-5 days of the menstrual cycle, it is preferred that the estrogen be administered in unit dosage form i.e., tablet or pill, with each unit providing the entire daily dosage. Such dosage units can be prepared by conventional methodology that is well known to one skilled in the art. In each dosage unit, the estrogen is combined with excipients, vehicles, pharmaceutically acceptable carriers, and colorants. For example, the following illustrates an acceptable estrogen composition of this invention. EXAMPLE 2
Ethinyl estradiol, 15 μg
Microcrystaline Cellulose Lactose, NF, Spray Dried Polacrillin Potassium, NF Magnesium Stearate Opadry Pink
Polyethylene Glycol, 1500, Flakes Water, Purified, USP Wax E (Pharma)
This invention also provides a contraceptive kit adapted for daily oral administration which comprises a total of 28 separate dosage units. In this kit, 23-25 dosage units each consisting of a combination of 40-500 μg trimegestone, 250 μg - 4 mg dienogest, or 250 μg - 4 mg drospirenone and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 μg ethinyl estradiol. The remaining 3-5 dosage units contain an estrogen at a daily dosage equivalent in estrogenic activity to 5-15 μg ethinyl estradiol. The daily dosage arrangements are preferably arranged in a blister pack or in a dial pack type tablet dispenser. Specific referred progestins and estrogens and the specifically preferred dosages of each combination dosage unit are described above.

Claims

WHAT IS CLAIMED IS:
1. A method of contraception which comprises administering to a female of child bearing age a combination of a progestin at a daily dosage selected from the group consisting of 40-500 μg trimegestone, 250 μg - 4 mg dienogest, and 250 μg - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 μg ethinyl estradiol for 23-25 days beginning on day 1 of the menstrual cycle; wherein the same dosage of the progestin and estrogen combination is administered in each of the 23-25 days, followed by the administration of an estrogen at a daily dosage equivalent in estrogenic activity to 5-15 μg ethinyl estradiol for 3-5 days; wherein the same dosage of the estrogen is administered in each of the 3-5 days; such that the number of days of administration of the progestin and estrogen combination plus the number of days of administration of estrogen is equal to 28 per menstrual cycle.
2. The method according to claim 1, wherein the estrogen is selected from the group consisting of ethinyl estradiol; 17β-estradiol; conjugated estrogens, USP; estrone or a salt thereof; and mestranol.
3. The method according to claim 2, wherein the estrogen is ethinyl estradiol.
4. The method according to claim 3, wherein the progestin/estrogen combination is administered for 24 days per menstrual cycle beginning on day 1 of the menstrual cycle.
5. The method according to claim 4 wherein the daily dosage of ethinyl estradiol during the 24 day administration period is 15 μg.
6. The method according to claim 5, wherein the progestin is trimegestone.
7. The method according to claim 6, wherein the daily dosage of trimegestone is 250 μg.
8. The method according to claim 6, wherein the daily dosage of trimegestone is 125 μg.
9. The method according to claim 6, wherein the daily dosage of trimegestone is 75 μg.
10. The method according to claim 6, wherein the daily dosage of trimegestone is 50 μg.
1 1. The method according to claim 6, wherein the daily dosage of trimegestone is 40 μg.
12. The method according to claim 5, wherein the progestin is dienogest.
13. The method according to claim 1 1, wherein the daily dosage of dienogest is 2 mg.
14. The method according to claim 1 1, wherein the daily dosage of dienogest is 1 mg.
15. The method according to claim 11, wherein the daily dosage of dienogest is 800 μg.
16. The method according to claim 11, wherein the daily dosage of dienogest is 750 μg.
17. The method according to claim 11 , wherein the daily dosage of dienogest is 500 μg.
18. The method according to claim 5, wherein the progestin is drospirenone.
19. The method according to claim 18, wherein the daily dosage of drospirenone is 3 mg.
20. The method according to claim 18, wherein the daily dosage of drospirenone is 2 mg.
21. The method according to claim 18, wherein the daily dosage of drospirenone is 1 mg.
22. The method according to claim 18, wherein the daily dosage of drospirenone is 500 μg.
23. A contraceptive kit adapted for daily oral administration which comprises 28 separate dosage units, 23-25 separate dosage units, said dosage units each containing a combination of a progestin at a dosage selected from the group consisting of 40-500 μg trimegestone, 250 μg - 4 mg dienogest, and 250 μg - 4 mg drospirenone, and an estrogen at a dosage equivalent in estrogenic activity to 10-20 μg ethinyl estradiol, wherein each of the dosage units contains the same dosage of progestin and estrogen; and 3-5 of said dosage units containing an estrogen at a daily dosage equivalent in estrogenic activity to 5-15 μg ethinyl estradiol, wherein each of the 3-5 dosage units contains the same dosage of estrogen.
24. The contraceptive kit according to claim 23, wherein the estrogen is selected from the group consisting of ethinyl estradiol; 17β-estradiol; conjugated estrogens, USP; estrone or a salt thereof; and mestranol.
25. The contraceptive kit according to claim 24, wherein the estrogen is ethinyl estradiol.
26. The contraceptive kit according to claim 25, wherein 24 of the 28 dosage units contain the progestin and estrogen combination, and 4 of the dosage units are progestin free.
PCT/US1997/012789 1996-07-26 1997-07-23 Progestin/estrogen oral contraceptive WO1998004267A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU38886/97A AU3888697A (en) 1996-07-26 1997-07-23 Progestin/estrogen oral contraceptive

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68785596A 1996-07-26 1996-07-26
US08/687,855 1996-07-26

Publications (1)

Publication Number Publication Date
WO1998004267A1 true WO1998004267A1 (en) 1998-02-05

Family

ID=24762149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/012789 WO1998004267A1 (en) 1996-07-26 1997-07-23 Progestin/estrogen oral contraceptive

Country Status (2)

Country Link
AU (1) AU3888697A (en)
WO (1) WO1998004267A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001015701A1 (en) * 1999-08-31 2001-03-08 Schering Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
USRE37564E1 (en) 1993-12-22 2002-02-26 Schering Aktiengesellschaft Composition for contraception
WO2003049744A1 (en) * 2001-12-05 2003-06-19 Barr Laboratories, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US7749987B2 (en) 1996-10-08 2010-07-06 Laboratorie Theramek Contraception method
US7855190B2 (en) 2003-07-16 2010-12-21 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
EP2305267A3 (en) * 1999-08-31 2011-08-17 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US20120220556A1 (en) * 2000-01-18 2012-08-30 Wolfgang Heil Drospirenone for hormone replacement therapy
US8415332B2 (en) 2004-10-07 2013-04-09 TEVA Woman's Health, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921843A (en) * 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
EP0491415A1 (en) * 1990-12-13 1992-06-24 Akzo Nobel N.V. Low estrogen oral contraceptives
EP0491438A1 (en) * 1990-12-17 1992-06-24 Akzo Nobel N.V. Contraceptive regimen
DE4104385C1 (en) * 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
DE4224534A1 (en) * 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Anti-ovulation agent for hormonal contraception
WO1995017194A1 (en) * 1993-12-22 1995-06-29 Schering Aktiengesellschaft Composition for a contraceptive comprising an estrogen and a gestagen
DE4411585A1 (en) * 1994-03-30 1995-10-05 Schering Ag Combined pharmaceutical preparation for hormonal contraception

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004330A1 (en) * 1988-10-20 1990-05-03 Pasquale Samuel A Contraception system and method
US4921843A (en) * 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
US5262408A (en) * 1990-12-13 1993-11-16 Akzo N.V. Low estrogen oral contraceptives
EP0491415A1 (en) * 1990-12-13 1992-06-24 Akzo Nobel N.V. Low estrogen oral contraceptives
EP0491438A1 (en) * 1990-12-17 1992-06-24 Akzo Nobel N.V. Contraceptive regimen
US5418228A (en) * 1990-12-17 1995-05-23 Akzo N.V. Contraceptive regimen
EP0499348A1 (en) * 1991-02-09 1992-08-19 Ehrlich, Marika, Dr. med. Ovulation-inhibiting agent for hormonal contraception
DE4104385C1 (en) * 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
DE4224534A1 (en) * 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Anti-ovulation agent for hormonal contraception
WO1995017194A1 (en) * 1993-12-22 1995-06-29 Schering Aktiengesellschaft Composition for a contraceptive comprising an estrogen and a gestagen
DE4344462A1 (en) * 1993-12-22 1995-06-29 Schering Ag Composition for contraception
DE4411585A1 (en) * 1994-03-30 1995-10-05 Schering Ag Combined pharmaceutical preparation for hormonal contraception
WO1995026730A1 (en) * 1994-03-30 1995-10-12 Schering Aktiengesellschaft Combined hormonal contraception pharmaceutical preparation

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44159E1 (en) 1993-12-22 2013-04-16 Bayer Schering Pharma Aktiengesellschaft Composition for contraception
USRE37564E1 (en) 1993-12-22 2002-02-26 Schering Aktiengesellschaft Composition for contraception
USRE37838E1 (en) 1993-12-22 2002-09-10 Schering Aktiengesellschaft Composition for contraception
USRE43916E1 (en) 1993-12-22 2013-01-08 Bayer Schering Pharma Aktiengesellschaft Composition for contraception
USRE38253E1 (en) 1993-12-22 2003-09-16 Schering Aktiengesellschaft Composition for contraception
US7749987B2 (en) 1996-10-08 2010-07-06 Laboratorie Theramek Contraception method
CZ300514B6 (en) * 1999-08-31 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical compositions containing ethynylestradiol and drospirenone
EP1380301A1 (en) * 1999-08-31 2004-01-14 Schering Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and dropirenone for use as a contraceptive
HRP20070188B1 (en) * 1999-08-31 2015-06-19 Bayer Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
AU2005202046B2 (en) * 1999-08-31 2008-11-20 Bayer Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
AU2005202046B9 (en) * 1999-08-31 2008-12-11 Bayer Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
EP2044941A1 (en) * 1999-08-31 2009-04-08 Bayer Schering Pharma AG Multiple-phase formulation of drospirenone and estradiol as a contraceptive
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
EP2305267A3 (en) * 1999-08-31 2011-08-17 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
AU2009200247B2 (en) * 1999-08-31 2010-07-01 Bayer Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
WO2001015701A1 (en) * 1999-08-31 2001-03-08 Schering Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US20120220556A1 (en) * 2000-01-18 2012-08-30 Wolfgang Heil Drospirenone for hormone replacement therapy
JP2005516913A (en) * 2001-12-05 2005-06-09 バー ラボラトリーズ インコーポレーティッド Oral contraceptives to prevent pregnancy and reduce premenstrual symptoms
US7858605B2 (en) 2001-12-05 2010-12-28 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
EP2305230A1 (en) * 2001-12-05 2011-04-06 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US7615545B2 (en) 2001-12-05 2009-11-10 Duramed Pharmaceuticals, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US7320969B2 (en) 2001-12-05 2008-01-22 Duramed Pharmaceuticals, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US8338396B2 (en) 2001-12-05 2012-12-25 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
WO2003049744A1 (en) * 2001-12-05 2003-06-19 Barr Laboratories, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US8680084B2 (en) 2001-12-05 2014-03-25 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US7855190B2 (en) 2003-07-16 2010-12-21 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
AU2010201022C1 (en) * 2003-07-16 2013-05-16 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
AU2010201022B2 (en) * 2003-07-16 2012-09-27 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US8450299B2 (en) 2004-10-07 2013-05-28 Teva Womans's Health, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US8415332B2 (en) 2004-10-07 2013-04-09 TEVA Woman's Health, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
US11617751B2 (en) 2006-07-06 2023-04-04 Bayer Pharma AG Pharmaceutical composition containing a tetrahydrofolic acid

Also Published As

Publication number Publication date
AU3888697A (en) 1998-02-20

Similar Documents

Publication Publication Date Title
US5858405A (en) Oral contraceptive
US5888543A (en) Oral contraceptives
US5747480A (en) Oral contraceptive
EP0956024B1 (en) Monophasic oral contraceptive method and kit comprising a combination of progestin and estrogen
US6479475B1 (en) Oral contraceptive
WO1998004246A2 (en) Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen
US6451778B1 (en) Oral contraceptive
EP0917466B1 (en) Oral contraceptive
EP0921804B1 (en) Biphasic oral contraceptive method and kit comprising a combination of a progestin and estrogen
WO1998004267A1 (en) Progestin/estrogen oral contraceptive
AU759925B2 (en) Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin
WO1998004266A1 (en) Oral contraceptive
WO1997041868A1 (en) Oral contraceptive
WO1997041870A1 (en) Oral contraceptive
WO1997041869A1 (en) Oral contraceptive
WO1997041871A1 (en) Oral contraceptive
WO1997041872A1 (en) Oral contraceptive
MXPA99000801A (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
MXPA99000883A (en) Oral contraceptive

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998508922

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase